Open AccessIntraductal prostate cancer: An aggressive subset of prostate cancers? Immunophenotypic evaluation
Author(s) -
Pinuccia Faviana,
Beatrice Belgio,
M. Panichi,
Francesca Manassero,
Cesare Selli,
Laura Boldrini
Publication year - 2022
Publication title -
urology annals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.355
H-Index - 20
eISSN - 0974-7834
pISSN - 0974-7796
DOI - 10.4103/ua.ua_131_20
Subject(s) - prostate cancer , medicine , prostate , oncology , cancer , tmprss2 , pca3 , erg , ezh2 , cancer research , pathology , disease , epigenetics , biology , covid-19 , gene , infectious disease (medical specialty) , ophthalmology , retinal , biochemistry
The presence of intraductal prostate cancer in a sample is often associated with large tumor volume, an advanced stage of the disease, a high Gleason score and an increased risk of recurrence, and resistance to androgen suppression and chemotherapy, which are also correlated with reduced progression-free survival and with postoperative, biochemical relapse.